Mankind Pharma Q4 FY26 Results: PAT Rs 559 Cr
- May 20, 2026
- Posted by: Kashish Aggarwal
- Category: News
Mankind Pharma Q4 FY26 results were declared on May 19, 2026. Mankind Pharma reported PAT of Rs 559 crore up 30.4% YoY from Rs 429 crore in Q4 FY25, on revenue of Rs 3,443 crore up 11.8% YoY. Mankind Pharma is a Pharmaceuticals company listed on Indian stock exchanges. This article covers the complete Mankind Pharma Q4 FY26 financial highlights, key performance factors, and FY27 outlook for investors tracking Mankind Pharma.
Click Here – Get Free Investment Predictions
Mankind Pharma Q4 FY26 Financial Highlights
| Metric | Q4 FY26 | Notes |
|---|---|---|
| PAT | Rs 559 crore | up 30.4% YoY from Rs 429 crore in Q4 FY25 |
| Revenue | Rs 3,443 crore | up 11.8% YoY |
Note: Consolidated. Domestic segment 85% of revenue grew 13.4% YoY. BSV speciality portfolio contributed. FY26 revenue Rs 17,300+ crore.
Mankind Pharma Q4 FY26 Performance Analysis
The Mankind Pharma Q4 FY26 results reflect Mankind Pharma’s operational performance during the January to March 2026 quarter. The company operates in the Pharmaceuticals space, a sector supported by India’s strong GDP growth and domestic demand. The Q4 FY26 results demonstrate continued business execution and operational resilience.
Screen the best stocks on the Univest Screener.
Investors tracking Mankind Pharma Q4 FY26 will focus on FY27 revenue guidance, margin trajectory, and management’s capital allocation commentary. Track Mankind Pharma on the Univest Screener for live fundamentals and real-time updates.
Key Business Factors for the company
Revenue and Operational Performance
The group performance reflects the January to March 2026 quarter, historically the year-end quarter with strong order execution and seasonality effects. India’s macroeconomic environment with GDP growth above 6.5% provided a constructive backdrop for the Pharmaceuticals sector during this period.
Profitability and Margin Trends
The listed company PAT of Rs 559 crore is up 30.4% YoY from Rs 429 crore in Q4 FY25. Sustaining profitability and improving operating margins will be key watchpoints for FY27 performance.
India Economic Context for Mankind Pharma
The January to March 2026 quarter saw strong domestic consumption, fiscal year-end capital expenditure cycles, and government infrastructure spending. The Reserve Bank of India’s supportive monetary stance and India’s resilient growth trajectory provided a stable environment for listed companies across sectors. For Mankind Pharma, operating in the Pharmaceuticals space, this macro backdrop supported demand conditions during the quarter.
FY27 Outlook and Growth Drivers
Following the group results, management commentary on FY27 revenue guidance, capex plans, and order pipeline will be the primary catalysts for investor sentiment. The Pharmaceuticals sector continues to benefit from India’s structural growth, rising domestic consumption, and government policy support.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.
Frequently Asked Questions on the business
What is it PAT?
Ans. The firm PAT was PAT of Rs 559 crore up 30.4% YoY from Rs 429 crore in Q4 FY25. Results declared May 19, 2026. Verify from NSE/BSE filings before making investment decisions.
What is the business revenue?
Ans. The firm revenue from operations was Rs 3,443 crore up 11.8% YoY. Check the Univest Screener for live data.
When were the company results announced?
Ans. The company results were announced on May 19, 2026, at the board of directors meeting approving audited Q4 and FY26 financial statements.
Is Mankind Pharma a good investment after Q4 FY26?
Ans. Investment decisions require individual assessment of fundamentals, valuation, risk tolerance, and investment horizon. This article is for educational purposes only. Consult a SEBI-registered financial advisor before investing.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.
